All Stories

  1. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

    Article • September 2019, Taylor & Francis

    Dr Leslie Citrome

  2. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm

    Article • September 2019, Taylor & Francis

    Dr Leslie Citrome

  3. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults

    Article • August 2019, Dove Medical Press

    Dr Leslie Citrome, justin faden

  4. Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

    Article • January 2019, Dove Medical Press

    Dr Leslie Citrome

  5. Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment

    Article • Expert Opinion on Pharmacotherapy, November 2018, Taylor & Francis

    Dr Leslie Citrome, justin faden

  6. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

    Article • October 2018, Dove Medical Press

    Dr Leslie Citrome

  7. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA

    Article • ClinicoEconomics and Outcomes Research, August 2018, Dove Medical Press

    Dr Leslie Citrome

  8. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective

    Article • Expert Review of Neurotherapeutics, April 2018, Taylor & Francis

    Dr Leslie Citrome

  9. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies

    Article • February 2018, Dove Medical Press

    Dr Leslie Citrome

  10. Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder

    Article • December 2017, Dove Medical Press

    Dr Leslie Citrome

  11. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study

    Article • CNS Spectrums, June 2017, Cambridge University Press

    Dr Leslie Citrome

  12. Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials

    Article • December 2016, Dove Medical Press

    Dr Leslie Citrome, Dr John B Edwards

  13. Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?

    Article • CNS Spectrums, December 2016, Cambridge University Press

    Dr Leslie Citrome

  14. Schizophrenia relapse, patient considerations, and potential role of lurasidone

    Article • Patient Preference and Adherence, August 2016, Dove Medical Press

    Dr Leslie Citrome

  15. Characteristics of binge eating disorder in relation to diagnostic criteria

    Article • August 2016, Dove Medical Press

    Dr Leslie Citrome

  16. Treatment of bipolar depression: making sensible decisions

    Article • CNS Spectrums, November 2014, Cambridge University Press

    Dr Leslie Citrome

  17. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

    Article • International Journal of Clinical Practice, September 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  18. Are you a Sunshine Superman? The US Sunshine Act and reporting requirements

    Article • International Journal of Clinical Practice, September 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  19. Psychiatrists’ Judgments About Antipsychotic Benefit and Risk Outcomes and Formulation in Schizophrenia Treatment

    Article • Psychiatric Services, September 2014, American Psychiatric Association

    Dr Leslie Citrome

  20. Where do accepted journal manuscripts come from?

    Article • International Journal of Clinical Practice, September 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  21. New Treatment Targets to Improve Symptoms in Schizophrenia

    Article • The Journal of Clinical Psychiatry, August 2014, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  22. Ride ‘em cowboy! The therapeutics of virtual reality technology and simulation

    Article • International Journal of Clinical Practice, July 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  23. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study – ADDENDUM

    Article • CNS Spectrums, July 2014, Cambridge University Press

    Dr Leslie Citrome

  24. Where do peer reviewers come from?

    Article • International Journal of Clinical Practice, June 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  25. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults

    Article • Current Medical Research and Opinion, May 2014, Informa Healthcare

    Dr Leslie Citrome

  26. Pharmaism: a tale of two perspectives

    Article • International Journal of Clinical Practice, May 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  27. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States

    Article • Journal of Medical Economics, May 2014, Informa Healthcare

    Dr Leslie Citrome

  28. Antipsychotics and diabetes: observational data (revision number 5)

    Article • May 2014, Diapedia

    Dr Leslie Citrome

  29. Asenapine review, part II: clinical efficacy, safety and tolerability

    Article • Expert Opinion on Drug Safety, May 2014, Informa Healthcare

    Dr Leslie Citrome

  30. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism

    Article • Expert Opinion on Drug Metabolism & Toxicology, May 2014, Informa Healthcare

    Dr Leslie Citrome

  31. Paging Dr Cohen, Paging Dr Cohen…An effect size interpretation is required STAT!

    Article • International Journal of Clinical Practice, April 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  32. Formulations: friendly, fast, forgiving and flexible

    Article • International Journal of Clinical Practice, March 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  33. A single‐dose, randomized, double‐blind, placebo‐controlled trial of sublingual asenapine for acute agitation

    Article • Acta Psychiatrica Scandinavica, March 2014, Wiley

    Dr Leslie Citrome

  34. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia

    Article • Schizophrenia Research, March 2014, Elsevier

    Dr Leslie Citrome

  35. The psychopharmacology of violence: making sensible decisions

    Article • CNS Spectrums, February 2014, Cambridge University Press

    Dr Leslie Citrome

  36. Where do editorials come from?

    Article • International Journal of Clinical Practice, February 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  37. Unmet Needs in the Treatment of Schizophrenia

    Article • The Journal of Clinical Psychiatry, February 2014, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  38. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed

    Article • Journal of Affective Disorders, February 2014, Elsevier

    Dr Leslie Citrome

  39. Battle for the planet of the apps

    Article • International Journal of Clinical Practice, January 2014, Hindawi Publishing Corporation

    Dr Leslie Citrome

  40. Psicofarmacologia e terapia elettroconvulsivante

    Article • January 2014, Springer Science + Business Media

    Dr Leslie Citrome

  41. The slow death of print

    Article • International Journal of Clinical Practice, December 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  42. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

    Article • CNS Spectrums, December 2013, Cambridge University Press

    Dr Leslie Citrome

  43. Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability

    Article • Evidence-Based Mental Health, December 2013, BMJ

    Dr Leslie Citrome

  44. Incidence of Cardiovascular Outcomes and Diabetes Mellitus Among Users of Second-Generation Antipsychotics

    Article • The Journal of Clinical Psychiatry, December 2013, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  45. Diagnoses Associated With Use of Atypical Antipsychotics in a Commercial Health Plan: A Claims Database Analysis

    Article • Clinical Therapeutics, December 2013, Elsevier

    Dr Leslie Citrome

  46. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study

    Article • CNS Spectrums, November 2013, Cambridge University Press

    Dr Leslie Citrome

  47. Holiday time! evidence-based flying revisited

    Article • International Journal of Clinical Practice, November 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  48. Number needed to treat can be helpful: A response to Alphs et al.

    Article • European Neuropsychopharmacology, November 2013, Elsevier

    Dr Leslie Citrome

  49. Number Needed to Harm Can Be Clinically Useful

    Article • The Journal of Nervous and Mental Disease, November 2013, Wolters Kluwer Health

    Dr Leslie Citrome

  50. Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed

    Article • Journal of Affective Disorders, November 2013, Elsevier

    Dr Leslie Citrome

  51. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

    Article • International Journal of Clinical Practice, October 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  52. Meta-analyses: editor's dream or nightmare?

    Article • International Journal of Clinical Practice, October 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  53. P.2.b.018 Post hoc analyses of levomilnacipran SR 40, 80, and 120 mg on functional outcomes in major depressive disorder

    Article • European Neuropsychopharmacology, October 2013, Elsevier

    Dr Leslie Citrome

  54. P.3.d.026 Comparative effectiveness of long-term treatment with atypical antipsychotics in patients with schizophrenia

    Article • European Neuropsychopharmacology, October 2013, Elsevier

    Dr Leslie Citrome

  55. P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia

    Article • European Neuropsychopharmacology, October 2013, Elsevier

    Dr Leslie Citrome

  56. P.3.d.047 Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months

    Article • European Neuropsychopharmacology, October 2013, Elsevier

    Dr Leslie Citrome

  57. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

    Article • International Journal of Clinical Practice, September 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  58. A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach

    Article • CNS Drugs, September 2013, Springer Science + Business Media

    Dr Leslie Citrome

  59. How we rate: is impact factor the most important measure?

    Article • International Journal of Clinical Practice, August 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  60. High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms

    Article • Journal of Clinical Psychopharmacology, August 2013, Wolters Kluwer Health

    Dr Leslie Citrome

  61. Back to the future: transitions, technology and tao

    Article • International Journal of Clinical Practice, July 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  62. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia

    Article • Expert Review of Neurotherapeutics, July 2013, Taylor & Francis

    Dr Leslie Citrome

  63. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: Challenges and therapeutic opportunities

    Article • Schizophrenia Research, July 2013, Elsevier

    Dr Leslie Citrome

  64. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents

    Article • Therapeutics and Clinical Risk Management, May 2013, Taylor & Francis

    Dr Leslie Citrome

  65. “Meta-guidelines” for the management of patients with schizophrenia

    Article • CNS Spectrums, April 2013, Cambridge University Press

    Dr Leslie Citrome, Dr Debbi Ann Morrissette, Stephen Stahl

  66. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed

    Article • International Journal of Clinical Practice, April 2013, Hindawi Publishing Corporation

    Dr Leslie Citrome

  67. Review: limited evidence on effects of haloperidol alone for rapid tranquillisation in psychosis-induced aggression

    Article • Evidence-Based Mental Health, February 2013, BMJ

    Dr Leslie Citrome

  68. Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy

    Article • Advances in Therapy, January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  69. Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy

    Article • Advances in Therapy, January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  70. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2013, Informa Healthcare

    Dr Leslie Citrome

  71. Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics

    Article • The Journal of Clinical Psychiatry, January 2013, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  72. Handbook of Treatment-resistant Schizophrenia

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  73. Psychopharmacological Approaches

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  74. A General Treatment Approach

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  75. Nonpharmacological Approaches

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  76. Somatic Treatments

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  77. Introduction

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  78. Conclusions

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  79. Schizophrenia: Violent Behavior

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  80. Dosing of Antipsychotics: What Evidence Do We Use?

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  81. Adherence: The Great Masquerader of Treatment-Resistance

    Article • January 2013, Springer Science + Business Media

    Dr Leslie Citrome

  82. 1046 – Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months

    Article • European Psychiatry, January 2013, Cambridge University Press

    Dr Leslie Citrome

  83. 1056 – Comparative effectiveness of long-term treatment with atypical antipsychotics in patients with schizophrenia

    Article • European Psychiatry, January 2013, Cambridge University Press

    Dr Leslie Citrome

  84. Antidepressant Therapy for Pain Associated With Osteoarthritis

    Article • PM&R, December 2012, Wiley

    Dr Leslie Citrome

  85. Addressing challenges in bipolar diagnosis: what do good clinicians already do?

    Article • Acta Psychiatrica Scandinavica, November 2012, Wiley

    Dr Leslie Citrome

  86. Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia

    Article • CNS Spectrums, November 2012, Cambridge University Press

    Dr Leslie Citrome

  87. A clinician’s best friend: the US National Library of Medicine’s patient resources

    Article • International Journal of Clinical Practice, October 2012, Hindawi Publishing Corporation

    Dr Leslie Citrome

  88. Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy

    Article • Advances in Therapy, September 2012, Springer Science + Business Media

    Dr Leslie Citrome

  89. Lurasidone for the Acute Treatment of Adults with Schizophrenia: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?

    Article • Clinical Schizophrenia & Related Psychoses, July 2012, Walsh Medical Media, LLC

    Dr Leslie Citrome

  90. Impact of the CATIE trial on antipsychotic prescribing

    Article • Schizophrenia Research, July 2012, Elsevier

    Dr Leslie Citrome

  91. Dissemination of clinical trial information: multiple audiences, multiple formats

    Article • June 2012, Cambridge University Press

    Dr Leslie Citrome

  92. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability

    Article • Expert Opinion on Drug Metabolism & Toxicology, May 2012, Informa Healthcare

    Dr Leslie Citrome

  93. Interview: The future of psychiatric medicine: clinical trials and beyond

    Article • Clinical Practice, May 2012, OMICS Publishing Group

    Dr Leslie Citrome

  94. Long-term safety and tolerability of lurasidone in schizophrenia

    Article • International Clinical Psychopharmacology, May 2012, Wolters Kluwer Health

    Dr Leslie Citrome

  95. Antidepressants and the relief of osteoarthritic pain - Findings from a study examining adjunctive duloxetine

    Article • International Journal of Clinical Practice, March 2012, Hindawi Publishing Corporation

    Dr Leslie Citrome

  96. Lurasidone for schizophrenia: what’s different?

    Article • Expert Review of Neurotherapeutics, March 2012, Taylor & Francis

    Dr Leslie Citrome

  97. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

    Article • International Journal of Clinical Practice, January 2012, Hindawi Publishing Corporation

    Dr Leslie Citrome

  98. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder

    Article • International Journal of Clinical Practice, January 2012, Hindawi Publishing Corporation

    Dr Leslie Citrome

  99. A Systematic Review of Duloxetine for Osteoarthritic Pain: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?

    Article • Postgraduate Medicine, January 2012, Taylor & Francis

    Dr Leslie Citrome

  100. Efficacy of iloperidone in the short‐term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo‐ and active‐controlled trials

    Article • Human Psychopharmacology Clinical and Experimental, December 2011, Wiley

    Dr Leslie Citrome

  101. Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings

    Article • CNS Drugs, December 2011, Springer Science + Business Media

    Dr Leslie Citrome

  102. Quantifying Clinical Relevance in Treatments for Psychiatric Disorders

    Article • Clinical Therapeutics, December 2011, Elsevier

    Dr Leslie Citrome

  103. Iloperidone

    Article • The Journal of Clinical Psychiatry, December 2011, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  104. Treatment-resistant schizophrenia: What's next

    Article • Schizophrenia Research, December 2011, Elsevier

    Dr Leslie Citrome

  105. Olanzapine–fluoxetine combination for the treatment of bipolar depression

    Article • Expert Opinion on Pharmacotherapy, October 2011, Informa Healthcare

    Dr Leslie Citrome

  106. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not

    Article • Expert Opinion on Pharmacotherapy, October 2011, Informa Healthcare

    Dr Leslie Citrome

  107. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia

    Article • Expert Opinion on Pharmacotherapy, October 2011, Informa Healthcare

    Dr Leslie Citrome

  108. Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis

    Article • Schizophrenia Research, September 2011, Elsevier

    Dr Leslie Citrome

  109. Psychopharmacology of Aggression in Schizophrenia

    Article • Schizophrenia Bulletin, August 2011, Oxford University Press (OUP)

    Dr Leslie Citrome

  110. Treatment-refractory schizophrenia: what is it and what has been done about it?

    Article • Neuropsychiatry, August 2011, OMICS Publishing Group

    Dr Leslie Citrome

  111. Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder

    Article • Clinical Drug Investigation, July 2011, Springer Science + Business Media

    Dr Leslie Citrome

  112. Evidence-based medicine: it’s not just about the evidence

    Article • International Journal of Clinical Practice, May 2011, Hindawi Publishing Corporation

    Dr Leslie Citrome

  113. Pathways to Aggression in Schizophrenia Affect Results of Treatment

    Article • Schizophrenia Bulletin, May 2011, Oxford University Press (OUP)

    Dr Leslie Citrome

  114. Role of sublingual asenapine in treatment of schizophrenia

    Article • Neuropsychiatric Disease and Treatment, May 2011, Taylor & Francis

    Dr Leslie Citrome

  115. Schizoaffective Disorder

    Article • CNS Drugs, April 2011, Springer Science + Business Media

    Dr Leslie Citrome

  116. A Randomized, Double-Blind, Parallel-Group, Fixed-Dose, Clinical Trial of Quetiapine at 600 Versus 1200 mg/d for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder

    Article • Journal of Clinical Psychopharmacology, April 2011, Wolters Kluwer Health

    Dr Leslie Citrome

  117. Number Needed to Treat: What It Is and What It Isn’t, and Why Every Clinician Should Know How to Calculate It

    Article • The Journal of Clinical Psychiatry, March 2011, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  118. Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics

    Article • Postgraduate Medicine, March 2011, Taylor & Francis

    Dr Leslie Citrome

  119. Drug safety evaluation of ziprasidone

    Article • Expert Opinion on Drug Safety, February 2011, Informa Healthcare

    Dr Leslie Citrome

  120. Likelihood to Be Helped or Harmed Can Assist in Clinical Decision-Making

    Article • The Journal of Clinical Psychiatry, February 2011, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  121. Does it work, will it work, and is it worth it? A call for papers (and reviewers) regarding effective treatments for psychiatric disorders

    Article • International Journal of Clinical Practice, February 2011, Hindawi Publishing Corporation

    Dr Leslie Citrome

  122. Lurasidone for Schizophrenia: A Brief Review of a New Second-Generation Antipsychotic

    Article • Clinical Schizophrenia & Related Psychoses, January 2011, Walsh Medical Media, LLC

    Dr Leslie Citrome

  123. High dose quetiapine in the treatment of psychosis due to traumatic brain injury

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 2011, Elsevier

    Dr Leslie Citrome

  124. The Tyranny of the P-value: Effect Size Matters

    Article • Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, January 2011, ScopeMed International Medical Journal Management and Indexing System

    Dr Leslie Citrome

  125. Psychiatric Illness, Psychotropic Medication, and Childhood Obesity

    Article • January 2011, Elsevier

    Dr Leslie Citrome

  126. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder

    Article • International Journal of Clinical Practice, December 2010, Hindawi Publishing Corporation

    Dr Leslie Citrome

  127. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?

    Article • Acta Psychiatrica Scandinavica, December 2010, Wiley

    Dr Leslie Citrome

  128. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

    Article • International Journal of Clinical Practice, December 2010, Hindawi Publishing Corporation

    Dr Leslie Citrome

  129. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion

    Article • Expert Opinion on Drug Metabolism & Toxicology, November 2010, Informa Healthcare

    Dr Leslie Citrome

  130. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?

    Article • International Journal of Clinical Practice, September 2010, Hindawi Publishing Corporation

    Dr Leslie Citrome

  131. Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

    Article • Postgraduate Medicine, July 2010, Taylor & Francis

    Dr Leslie Citrome

  132. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults

    Article • Expert Review of Neurotherapeutics, July 2010, Taylor & Francis

    Dr Leslie Citrome

  133. The importance of a good night's sleep: An open-label trial of the sodium salt of γ-hydroxybutyric acid in insomnia associated with schizophrenia

    Article • Schizophrenia Research, July 2010, Elsevier

    Dr Leslie Citrome

  134. Authors' Submission Toolkit: A practical guide to getting your research published

    Article • Current Medical Research and Opinion, June 2010, Informa Healthcare

    Dr Leslie Citrome, Mr Leighton Chipperfield

  135. Nine out of ten doctors prefer Camels! Three brief essays regarding how we use and abuse statistics

    Article • International Journal of Clinical Practice, June 2010, Hindawi Publishing Corporation

    Dr Leslie Citrome

  136. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities

    Article • Schizophrenia Research, June 2010, Elsevier

    Dr Leslie Citrome

  137. Evidence-based flying: a new paradigm for frequent flyers

    Article • International Journal of Clinical Practice, May 2010, Hindawi Publishing Corporation

    Dr Leslie Citrome

  138. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

    Article • International Journal of Clinical Practice, May 2010, Hindawi Publishing Corporation

    Dr Leslie Citrome

  139. Spirituality, Schizophrenia, and State Hospitals: Program Description and Characteristics of Self-Selected Attendees of a Spirituality Therapeutic Group

    Article • Psychiatric Quarterly, April 2010, Springer Science + Business Media

    Dr Leslie Citrome

  140. Citability of Original Research and Reviews in Journals and Their Sponsored Supplements

    Article • PLoS ONE, March 2010, PLOS

    Dr Leslie Citrome

  141. Book Review: Pandemic Influenza Preparedness and Response, a WHO Guidance Document

    Article • Annals of Pharmacotherapy, February 2010, SAGE Publications

    Dr Leslie Citrome

  142. How to Efficiently Maintain Your Own Electronic Resource Library

    Article • The Journal of Clinical Psychiatry, February 2010, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  143. Relative vs. absolute measures of benefit and risk: what’s the difference?

    Article • Acta Psychiatrica Scandinavica, January 2010, Wiley

    Dr Leslie Citrome

  144. Datapoints: Depot Antipsychotic Use in New York State Hospitals, 1994 to 2009

    Article • Psychiatric Services, January 2010, American Psychiatric Association

    Dr Leslie Citrome

  145. Stimulant-Induced Trichotillomania

    Article • Substance Abuse, January 2010, SAGE Publications

    Dr Leslie Citrome

  146. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

    Article • Schizophrenia Research, December 2009, Elsevier

    Dr Leslie Citrome

  147. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

    Article • International Journal of Clinical Practice, December 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  148. The Impact of Ethnicity on Metabolic Outcomes During Treatment With Antipsychotics

    Article • The Journal of Clinical Psychiatry, November 2009, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  149. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

    Article • International Journal of Clinical Practice, November 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  150. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection

    Article • Patient Preference and Adherence, November 2009, Taylor & Francis

    Dr Leslie Citrome

  151. Teaching the philosophy and tools of evidence‐based medicine: misunderstandings and solutions*

    Article • Journal of Evidence-Based Medicine, November 2009, Wiley

    Dr Leslie Citrome

  152. How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do

    Article • International Journal of Clinical Practice, October 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  153. Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications

    Article • Current Drug Safety, September 2009, Bentham Science Publishers

    Dr Leslie Citrome

  154. Using oral ziprasidone effectively: the food effect and dose-response

    Article • Advances in Therapy, August 2009, Springer Science + Business Media

    Dr Leslie Citrome

  155. GABAB Receptors, Schizophrenia and Sleep Dysfunction

    Article • CNS Drugs, August 2009, Springer Science + Business Media

    Dr Leslie Citrome

  156. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

    Article • International Journal of Clinical Practice, August 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  157. How Dosing of Ziprasidone in a State Hospital System Differs From Product Labeling

    Article • The Journal of Clinical Psychiatry, July 2009, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  158. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?

    Article • Expert Review of Neurotherapeutics, July 2009, Taylor & Francis

    Dr Leslie Citrome

  159. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

    Article • Expert Opinion on Pharmacotherapy, June 2009, Informa Healthcare

    Dr Leslie Citrome

  160. Adding Lithium or Anticonvulsants to Antipsychotics for the Treatment of Schizophrenia: Useful Strategy or Exercise in Futility?

    Article • The Journal of Clinical Psychiatry, June 2009, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  161. Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response

    Article • The Journal of Clinical Psychiatry, June 2009, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  162. GABAB Receptors, Schizophrenia and Sleep Dysfunction

    Article • CNS Drugs, June 2009, Springer Science + Business Media

    Dr Leslie Citrome

  163. Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia

    Article • Journal of Clinical Psychopharmacology, June 2009, Wolters Kluwer Health

    Dr Leslie Citrome

  164. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials

    Article • Schizophrenia Research, June 2009, Elsevier

    Dr Leslie Citrome

  165. Systematic reviews: much ado about a lot

    Article • International Journal of Clinical Practice, June 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  166. Posters can be a sticking point: Letter in response to comments by Akhras et al.

    Article • International Journal of Clinical Practice, June 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  167. Egg Consumption and Risk of Type 2 Diabetes in Men and Women

    Article • Diabetes Care, June 2009, American Diabetes Association

    Dr Leslie Citrome

  168. Staff and Patient Views of the Reasons for Aggressive Incidents: A Prospective, Incident-Based Study

    Article • Psychiatric Quarterly, May 2009, Springer Science + Business Media

    Dr Leslie Citrome

  169. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol

    Article • Schizophrenia Research, May 2009, Elsevier

    Dr Leslie Citrome

  170. All Antipsychotics Are Equal, but Some Are More Equal Than Others

    Article • The Journal of Clinical Psychiatry, March 2009, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  171. “Stat” Medication Administration Predicts Hospital Discharge

    Article • Psychiatric Quarterly, March 2009, Springer Science + Business Media

    Dr Leslie Citrome

  172. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder

    Article • Schizophrenia Research, March 2009, Elsevier

    Dr Leslie Citrome

  173. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions

    Article • International Journal of Clinical Practice, March 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  174. JUPITER: wake up and smell the coffee - The absolute and relative merits of statin use

    Article • International Journal of Clinical Practice, March 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  175. A review of tolerability and abuse liability of γ-hydroxybutyric acid for insomnia in patients with schizophrenia

    Article • Clinical Therapeutics, January 2009, Elsevier

    Dr Leslie Citrome

  176. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?

    Article • Expert Review of Neurotherapeutics, January 2009, Taylor & Francis

    Dr Leslie Citrome

  177. Efficacy versus Effectiveness

    Article • January 2009, SAGE Publications

    Dr Leslie Citrome

  178. Olanzapine pamoate: a stick in time?

    Article • International Journal of Clinical Practice, January 2009, Hindawi Publishing Corporation

    Dr Leslie Citrome

  179. Show Me the Evidence: Now What Do I Do with It?

    Article • Southern Medical Journal, December 2008, Southern Medical Association

    Dr Leslie Citrome

  180. Olanzapine: review of safety 2008

    Article • Expert Opinion on Drug Safety, November 2008, Informa Healthcare

    Dr Leslie Citrome

  181. Book Review

    Article • Acta Psychiatrica Scandinavica, October 2008, Wiley

    Dr Leslie Citrome

  182. A new rating scale for negative symptoms: The Motor-Affective-Social Scale

    Article • Psychiatry Research, September 2008, Elsevier

    Dr Leslie Citrome

  183. Public-Academic Partnerships: Integrating State Psychiatric Hospital Treatment and Clinical Research

    Article • Psychiatric Services, September 2008, American Psychiatric Association

    Dr Leslie Citrome

  184. Loss aversion in schizophrenia

    Article • Schizophrenia Research, August 2008, Elsevier

    Dr Leslie Citrome

  185. Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder

    Article • Journal of Clinical Psychopharmacology, August 2008, Wolters Kluwer Health

    Dr Leslie Citrome

  186. Valproate: do formulations matter?

    Article • Journal of Clinical Pharmacy and Therapeutics, August 2008, Hindawi Publishing Corporation

    Dr Leslie Citrome

  187. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks

    Article • Expert Review of Neurotherapeutics, July 2008, Taylor & Francis

    Dr Leslie Citrome

  188. Heterogeneity of violence in schizophrenia and implications for long-term treatment

    Article • International Journal of Clinical Practice, June 2008, Hindawi Publishing Corporation

    Dr Leslie Citrome

  189. Antiepileptics in the Treatment of Schizophrenia

    Article • June 2008, Taylor & Francis

    Dr Leslie Citrome

  190. EFFECT OF ZIPRASIDONE DOSE ON RATES OF MEDICATION DISCONTINUATION IN ACUTE SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER

    Article • Schizophrenia Research, June 2008, Elsevier

    Dr Leslie Citrome

  191. Compelling or irrelevant? Using number needed to treat can help decide

    Article • Acta Psychiatrica Scandinavica, June 2008, Wiley

    Dr Leslie Citrome

  192. Datapoints: Did CATIE Influence Antipsychotic Use?

    Article • Psychiatric Services, May 2008, American Psychiatric Association

    Dr Leslie Citrome

  193. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia

    Article • International Journal of Clinical Practice, April 2008, Hindawi Publishing Corporation

    Dr Leslie Citrome

  194. Current guidelines and their recommendations for prolactin monitoring in psychosis

    Article • Journal of Psychopharmacology, March 2008, SAGE Publications

    Dr Leslie Citrome

  195. The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness

    Article • Journal of Psychopharmacology, March 2008, SAGE Publications

    Dr Leslie Citrome

  196. Antipsychotics and hyperprolactinaemia: Clinical recommendations

    Article • Journal of Psychopharmacology, March 2008, SAGE Publications

    Dr Leslie Citrome

  197. Creating a more productive, clutter-free, paperless office: a primer on scanning, storage and searching of PDF documents on personal computers

    Article • International Journal of Clinical Practice, February 2008, Hindawi Publishing Corporation

    Dr Leslie Citrome

  198. Motor-Affective Social Scale

    Article • January 2008, American Psychological Association (APA)

    Dr Leslie Citrome

  199. Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?

    Article • Postgraduate Medicine, January 2008, Taylor & Francis

    Dr Leslie Citrome

  200. Quetiapine

    Article • CNS Drugs, January 2008, Springer Science + Business Media

    Dr Leslie Citrome

  201. Book Review: Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 2nd Edition

    Article • Annals of Pharmacotherapy, January 2008, SAGE Publications

    Dr Leslie Citrome

  202. Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation

    Article • The Journal of Clinical Psychiatry, December 2007, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  203. Lamotrigine as Add-On Therapy in Schizophrenia

    Article • Journal of Clinical Psychopharmacology, December 2007, Wolters Kluwer Health

    Dr Leslie Citrome

  204. Olanzapine: interpreting the label change

    Article • International Journal of Clinical Practice, November 2007, Hindawi Publishing Corporation

    Dr Leslie Citrome

  205. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility

    Article • International Clinical Psychopharmacology, November 2007, Wolters Kluwer Health

    Dr Leslie Citrome

  206. Reducing Inpatient Aggression: Does Paying Attention Pay Off?

    Article • Psychiatric Quarterly, October 2007, Springer Science + Business Media

    Dr Leslie Citrome

  207. Atypical Antipsychotics, Elderly Patients, and Mortality Risk

    Article • Southern Medical Journal, October 2007, Southern Medical Association

    Dr Leslie Citrome

  208. Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics

    Article • Annals of Pharmacotherapy, October 2007, SAGE Publications

    Dr Leslie Citrome

  209. Reviewing CATIE for clinicians:balancing benefit and risk using evidence-based medicine tools

    Article • Current Medical Research and Opinion, September 2007, Informa Healthcare

    Dr Leslie Citrome

  210. Show Me the Evidence: Using Number Needed to Treat

    Article • Southern Medical Journal, September 2007, Southern Medical Association

    Dr Leslie Citrome

  211. Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials

    Article • CNS Drug Reviews, June 2007, Wiley

    Dr Leslie Citrome

  212. Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine

    Article • Journal of Clinical Psychopharmacology, June 2007, Wolters Kluwer Health

    Dr Leslie Citrome

  213. Intramuscular Aripiprazole in the Control of Agitation

    Article • Journal of Psychiatric Practice, May 2007, Wolters Kluwer Health

    Dr Leslie Citrome

  214. Paliperidone: quo vadis?

    Article • International Journal of Clinical Practice, March 2007, Hindawi Publishing Corporation

    Dr Leslie Citrome

  215. Health Care Informatics: A Skills-Based Resource

    Article • Journal of Pharmacy Technology, March 2007, SAGE Publications

    Dr Leslie Citrome

  216. The role of adherence to medication in the effectiveness of long-term treatment of schizophrenia

    Article • European Psychiatry, March 2007, Cambridge University Press

    Dr Leslie Citrome

  217. The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 2: Long-Term Treatment

    Article • The Journal of Clinical Psychiatry, February 2007, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  218. The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 1: Acute Treatment

    Article • The Journal of Clinical Psychiatry, January 2007, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  219. Datapoints: The Ups and Downs of Dosing Second-Generation Antipsychotics

    Article • Psychiatric Services, January 2007, American Psychiatric Association

    Dr Leslie Citrome

  220. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

    Article • Neuropsychiatric Disease and Treatment, December 2006, Taylor & Francis

    Dr Leslie Citrome

  221. Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia

    Article • Journal of Clinical Psychopharmacology, December 2006, Wolters Kluwer Health

    Dr Leslie Citrome

  222. Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder

    Article • Journal of Neuropsychiatry, November 2006, American Psychiatric Association

    Dr Leslie Citrome

  223. Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment

    Article • Evidence-Based Mental Health, August 2006, BMJ

    Dr Leslie Citrome

  224. Incidence, Prevalence, and Surveillance for Diabetes in New York State Psychiatric Hospitals, 1997-2004

    Article • Psychiatric Services, August 2006, American Psychiatric Association

    Dr Leslie Citrome

  225. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?

    Article • International Journal of Clinical Practice, July 2006, Hindawi Publishing Corporation

    Dr Leslie Citrome

  226. Atypical Antipsychotic Agents in the Treatment of Violent Patients With Schizophrenia and Schizoaffective Disorder

    Article • Archives of General Psychiatry, June 2006, American Medical Association (AMA)

    Dr Leslie Citrome

  227. Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine

    Article • Journal of Clinical Psychopharmacology, June 2006, Wolters Kluwer Health

    Dr Leslie Citrome

  228. Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics

    Article • Journal of Clinical Psychopharmacology, June 2006, Wolters Kluwer Health

    Dr Leslie Citrome

  229. Efficacy of Ziprasidone Against Hostility in Schizophrenia

    Article • The Journal of Clinical Psychiatry, April 2006, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  230. The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes

    Article • Diabetes Care, January 2006, American Diabetes Association

    Dr Leslie Citrome

  231. Dosing of Quetiapine in Schizophrenia

    Article • The Journal of Clinical Psychiatry, December 2005, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  232. Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder

    Article • Psychiatry Research Neuroimaging, November 2005, Elsevier

    Dr Leslie Citrome

  233. Metabolic Syndrome and Cardiovascular Disease

    Article • Journal of Psychopharmacology, November 2005, SAGE Publications

    Dr Leslie Citrome

  234. Do guidelines for severe mental illness promote physical health and well-being?

    Article • Journal of Psychopharmacology, November 2005, SAGE Publications

    Dr Leslie Citrome

  235. Diabetes and schizophrenia 2005: are we any closer to understanding the link?

    Article • Journal of Psychopharmacology, November 2005, SAGE Publications

    Dr Leslie Citrome

  236. Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

    Article • European Neuropsychopharmacology, October 2005, Elsevier

    Dr Leslie Citrome

  237. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

    Article • The Journal of Clinical Psychiatry, August 2005, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  238. Dosing of Second-Generation Antipsychotic Medication in a State Hospital System

    Article • Journal of Clinical Psychopharmacology, August 2005, Wolters Kluwer Health

    Dr Leslie Citrome

  239. Metabolic Issues in Patients with Severe Mental Illness

    Article • Southern Medical Journal, July 2005, Southern Medical Association

    Dr Leslie Citrome

  240. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation

    Article • Schizophrenia Research, July 2005, Elsevier

    Dr Leslie Citrome

  241. Focus on The clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus

    Article • The International Journal of Neuropsychopharmacology, June 2005, Oxford University Press (OUP)

    Dr Leslie Citrome

  242. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

    Article • Neuroscience Letters, May 2005, Elsevier

    Dr Leslie Citrome

  243. Book Review: Essential Psychopharmacology: The Prescriber's Guide

    Article • Annals of Pharmacotherapy, May 2005, SAGE Publications

    Dr Leslie Citrome

  244. Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment

    Article • Pharmacological Research, April 2005, Elsevier

    Dr Leslie Citrome

  245. Antipsychotic Medication and Diabetes Mellitusrs

    Article • The Journal of Clinical Psychiatry, March 2005, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  246. Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients

    Article • American Journal of Psychiatry, March 2005, American Psychiatric Association

    Dr Leslie Citrome

  247. The many faces of bipolar disorder

    Article • Postgraduate Medicine, February 2005, Taylor & Francis

    Dr Leslie Citrome

  248. COMMENTARY: Bipolar disorder is a potentially fatal disease

    Article • Postgraduate Medicine, February 2005, Taylor & Francis

    Dr Leslie Citrome

  249. Latest therapies for bipolar disorder

    Article • Postgraduate Medicine, February 2005, Taylor & Francis

    Dr Leslie Citrome

  250. Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate

    Article • The Journal of Clinical Pharmacology, January 2005, Wiley

    Dr Leslie Citrome

  251. Toward Convergence in the Medication Treatment of Bipolar Disorder and Schizophrenia

    Article • Harvard Review of Psychiatry, January 2005, Wolters Kluwer Health

    Dr Leslie Citrome

  252. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder

    Article • Journal of Psychiatric Research, January 2005, Elsevier

    Dr Leslie Citrome

  253. Testing for diabetes

    Article • The British Journal of Psychiatry, January 2005, Royal College of Psychiatrists

    Dr Leslie Citrome

  254. The promise of atypical antipsychotics

    Article • Postgraduate Medicine, October 2004, Taylor & Francis

    Dr Leslie Citrome

  255. Ziprasidone versus haloperidol for the treatment of agitation

    Article • Annals of Emergency Medicine, October 2004, Elsevier

    Dr Leslie Citrome

  256. Antihostility Effects of Adjunctive Divalproex

    Article • Psychiatric Services, September 2004, American Psychiatric Association

    Dr Leslie Citrome

  257. Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients

    Article • Psychiatric Services, September 2004, American Psychiatric Association

    Dr Leslie Citrome

  258. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes

    Article • Diabetes Care, August 2004, American Diabetes Association

    Dr Leslie Citrome

  259. A Study of the Safety, Efficacy, and Tolerability of Switching From the Standard Delayed Release Preparation of Divalproex Sodium to the Extended Release Formulation in Patients With Schizophrenia

    Article • Journal of Clinical Psychopharmacology, June 2004, Wolters Kluwer Health

    Dr Leslie Citrome

  260. Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia

    Article • The Journal of Clinical Psychiatry, April 2004, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  261. Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol

    Article • Journal of Clinical Psychopharmacology, April 2004, Wolters Kluwer Health

    Dr Leslie Citrome

  262. Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol

    Article • Journal of Clinical Psychopharmacology, April 2004, Wolters Kluwer Health

    Dr Leslie Citrome

  263. Adjunctive Divalproex and Hostility Among Patients With Schizophrenia Receiving Olanzapine or Risperidone

    Article • Psychiatric Services, March 2004, American Psychiatric Association

    Dr Leslie Citrome

  264. Flexible oral olanzapine dosing in acutely agitated people is immediately effective in reducing symptoms

    Article • Evidence-Based Mental Health, February 2004, BMJ

    Dr Leslie Citrome

  265. Prolactin Levels in Schizophrenia and Schizoaffective Disorder Patients Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol

    Article • The Journal of Clinical Psychiatry, January 2004, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  266. New Treatments for Agitation

    Article • Psychiatric Quarterly, January 2004, Springer Science + Business Media

    Dr Leslie Citrome

  267. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents

    Article • Drugs of Today, January 2004, Prous Science

    Dr Leslie Citrome

  268. Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus

    Article • Annals of Pharmacotherapy, December 2003, SAGE Publications

    Dr Leslie Citrome

  269. P.2.063 Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycemics

    Article • European Neuropsychopharmacology, October 2003, Elsevier

    Dr Leslie Citrome

  270. COMT158 polymorphism and hostility

    Article • American Journal of Medical Genetics Part B Neuropsychiatric Genetics, September 2003, Wiley

    Dr Leslie Citrome

  271. Characteristics of Assaultive Behavior Among Psychiatric Inpatients

    Article • Psychiatric Services, July 2003, American Psychiatric Association

    Dr Leslie Citrome

  272. Efficacy should drive atypical antipsychotic treatment

    Article • BMJ, February 2003, BMJ

    Dr Leslie Citrome

  273. Atypical antipsychotics for acute agitation

    Article • Postgraduate Medicine, December 2002, Taylor & Francis

    Dr Leslie Citrome

  274. Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment

    Article • The Journal of Clinical Psychiatry, October 2002, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  275. Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia

    Article • Biological Psychiatry, October 2002, Elsevier

    Dr Leslie Citrome

  276. Datapoints: Use of Mood Stabilizers Among Patients With Schizophrenia, 1994-2001

    Article • Psychiatric Services, October 2002, American Psychiatric Association

    Dr Leslie Citrome

  277. Managing Treatment-Resistant Schizophrenia: Evidence from Randomized Clinical Trials

    Article • Journal of Psychiatric Practice, July 2002, Wolters Kluwer Health

    Dr Leslie Citrome

  278. Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association

    Article • Journal of Clinical Psychopharmacology, June 2002, Wolters Kluwer Health

    Dr Leslie Citrome

  279. Atypical antipsychotics: revolutionary or incremental advance?

    Article • Expert Review of Neurotherapeutics, January 2002, Taylor & Francis

    Dr Leslie Citrome

  280. Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence

    Article • Harvard Review of Psychiatry, January 2002, Wolters Kluwer Health

    Dr Leslie Citrome

  281. Antiaggressive Effect of Quetiapine in a Patient With Schizoaffective Disorder

    Article • The Journal of Clinical Psychiatry, November 2001, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  282. Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia

    Article • Psychiatric Services, November 2001, American Psychiatric Association

    Dr Leslie Citrome

  283. Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial

    Article • Journal of Clinical Psychopharmacology, August 2001, Wolters Kluwer Health

    Dr Leslie Citrome

  284. Alcohol abuse, schizophrenia, and atypical antipsychotics

    Article • European Neuropsychopharmacology, January 2001, Elsevier

    Dr Leslie Citrome

  285. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder

    Article • European Neuropsychopharmacology, January 2001, Elsevier

    Dr Leslie Citrome

  286. FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia

    Article • European Psychiatry, October 2000, Cambridge University Press

    Dr Leslie Citrome

  287. Changes in Use of Valproate and Other Mood Stabilizers for Patients With Schizophrenia From 1994 to 1998

    Article • Psychiatric Services, May 2000, American Psychiatric Association

    Dr Leslie Citrome

  288. High-Dose Treatment With Haloperidol: The Effect of Dose Reduction

    Article • Journal of Clinical Psychopharmacology, April 2000, Wolters Kluwer Health

    Dr Leslie Citrome

  289. Pharmacological Interventions for Preventing Violence Among the Mentally Ill with Co-Occurring Personality Disorders

    Article • January 2000, Springer Science + Business Media

    Dr Leslie Citrome

  290. Management of Violence in Schizophrenia

    Article • Psychiatric Annals, January 2000, SLACK, Inc.

    Dr Leslie Citrome

  291. VIOLENT PATIENTS IN THE EMERGENCY SETTING

    Article • Psychiatric Clinics of North America, December 1999, Elsevier

    Dr Leslie Citrome

  292. Violence in Schizophrenia

    Article • Journal of Psychiatric Practice, November 1999, Wolters Kluwer Health

    Dr Leslie Citrome

  293. Schizophrenia: violence and comorbidity

    Article • Current Opinion in Psychiatry, January 1999, Wolters Kluwer Health

    Dr Leslie Citrome

  294. Safety of Accutane with possible depression

    Article • Postgraduate Medicine, October 1998, Taylor & Francis

    Dr Leslie Citrome

  295. Psychopharmacology of Violence: Part II: Beyond the Acute Episode

    Article • Psychiatric Annals, October 1997, SLACK, Inc.

    Dr Leslie Citrome

  296. Psychopharmacology of Violence: Part I: Assessment and Acute Treatment

    Article • Psychiatric Annals, October 1997, SLACK, Inc.

    Dr Leslie Citrome

  297. Layoffs, reductions-in-force, downsizing, rightsizing: The case of a state psychiatric hospital

    Article • Administration and Policy in Mental Health and Mental Health Services Research, July 1997, Springer Science + Business Media

    Dr Leslie Citrome

  298. New antipsychotic medications

    Article • Postgraduate Medicine, February 1997, Taylor & Francis

    Dr Leslie Citrome

  299. Adjunctive Nadolol in the Treatment of Acutely Aggressive Schizophrenic Patients

    Article • The Journal of Clinical Psychiatry, October 1996, Physicians Postgraduate Press, Inc

    Dr Leslie Citrome

  300. Transient Elevations in Pancreatic Enzymes in Response to a Cholinesterase Inhibitor

    Article • Clinical Neuropharmacology, October 1995, Wolters Kluwer Health

    Dr Leslie Citrome

  301. Clinical and administrative consequences of a reduced census on a Psychiatric Intensive Care Unit

    Article • Psychiatric Quarterly, September 1995, Springer Science + Business Media

    Dr Leslie Citrome

  302. Personal computers in risk management and incident reporting

    Article • Administration and Policy in Mental Health and Mental Health Services Research, May 1995, Springer Science + Business Media

    Dr Leslie Citrome